Interferon-α after autologous stem cell transplantation in pediatric patients with advanced Hodgkin's lymphoma

Bone Marrow Transplantation

Volumn 38, Issue 5, 2006, Pages 345-349

  Petropoulos, D ^a   Worth, L L ^a   Mullen, C A ^a,b   Lockhart, S ^c   Choroszy, M ^a   Chan, K W ^a,d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c Children's Hospital of Austin   (United States)

^d TEXAS TRANSPLANT INSTITUTE   (United States)

Author keywords

Autologous stem cell transplant, interferon ; Children; Hodkin's lymphoma

Indexed keywords

ALPHA INTERFERON; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; IBUPROFEN; MELPHALAN; MITOXANTRONE; PARACETAMOL; THIOTEPA;

ADOLESCENT; ADULT; ADVANCED CANCER; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHILDHOOD CANCER; CHILL; CLINICAL ARTICLE; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HORMONE SUBSTITUTION; HUMAN; HYPERTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MALE; PEDIATRICS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SCHOOL CHILD; SURVIVAL TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHILD; FEMALE; HODGKIN DISEASE; HUMANS; INTERFERON-ALPHA; MALE; RECURRENCE; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 33747344790     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705458     Document Type: Article

References (28)

1. Kobninsky N, Sposto R, Shah NR, Anderson JR, DeLaat C, Morse M et al. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine and L-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912. J Clin Oncol 2001; 19: 2390-2396.
2. Williams CD, Goldstone AH, Pearce R, Green S, Armitage JO, Carella A et al. Autologous bone marrow transplantation for pediatric Hodgkin's disease: A case-matched comparison with adult patients by the European Bone Marrow Transplant Group Lymphoma Registry. J Clin Oncol 1993; 11: 2243-2249.
3. Baker KS, Gordon BG, Gross TG, Abromowitch MA, Lyden ER, Lynch JC et al. Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents. J Clin Oncol 1999; 17: 825-831.
4. Lieskovsky YE, Donaldson SS, Torres MA, Wong RM, Amylon MD, Link MP et al. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices. J Clin Oncol 2004; 22: 4532-4540.
5. Verdeguer A, Pardo N, Madero L, Martinez A, Bureo E, Fernandez JM et al. Autologous stem cell transplantation for advanced Hodgkin's disease in children. Bone Marrow Transplant 2000; 25: 31-34.
6. Stoneham S, Ashley S, Pinkerton CR, Wallace WH, Shankar AG. Outcome after autologous hematopoietic stem cell transplantation in relapsed or refractory childhood Hodgkin disease. J Pediatr Hematol Oncol 2004; 26: 740-745.
7. Stiff PJ, Unger JM, Forman SJ, McCall AR, LeBlanc M, Nademanee AP et al. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: A Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant 2003; 9: 529-539.
8. Stewart DA, Guo D, Gluck S, Morris D, Chaudhry A, deMetz C et al. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant 2000; 26: 383-388.
9. Mundt AJ, Sibley G, Williams S, Hallahan D, Nautiyal J, Weichselbaum RR. Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/ refractory Hodgkin's disease. Int J Radiat Oncol Biol Phys 1995; 33: 261-270.
10. Rapoport AP, Guo C, Badros A, Hakimian R, Akpek G, Kiggundu E et al. Autologous stem cell transplantation followed by consolidation chemotherapy for relapsed or refractory Hodgkin's lymphoma. Bone Marrow Transplant 2004; 34: 883-890.
11. Rooney CM, Bollard C, Huls MH, Gahn B, Gottschalk S, Wagner HJ et al. Immunotherapy for Hodgkin's disease. Ann Hematol 2002; 81 (Suppl 2): S39-S42.
12. Rybak ME, McCarroll K, Bernard S, Lester E, Barcos M, Ozer H et al. Interferon therapy of relapsed and refractory Hodgkin's disease: Cancer and Leukemia Group B Study 8652. J Biol Response Modifiers 1990; 9: 1-4.
13. Leavitt RD, Ratanatharathorn V, Ozer H, Ultmann JE, Portlack C, Myers JW et al. Alfa-2b interferon in the treatment of Hodgkin's disease and non-Hodgkin's lymphoma. Semin Oncol 1987; 14 (Suppl 2): 18-23.
14. Maloisel F, Voillat L, Chenard MP, Boehn A, Lioure B, Oberling F. Interferon-α-2b in the management of patients with relapsed and/or refractory Hodgkin's disease. Ann Oncol 1997; 8: 405-406.
15. Aviles A, Diaz-Maqueo JC, Talavera A, Nambo MJ, Garcia EL. Maintenance therapy with interferon Alfa 2b in Hodgkin disease. Leukemia Lymphoma 1998; 30: 651-656.
16. Parmar S, Platanias LC. Interferons: Mechanisms of action and clinical applications. Curr Opin Oncol 2003; 15: 431-439.
17. Tompkins WA. Immunomodulation and therapeutic effects of the oral use of interferon-alpha: Mechanism of action. J Interferon Cytokine Res 1999; 19: 817-828.
18. Fidler IJ. Angiogeneis and cancer metastasis. Cancer J 2000; 6 (Suppl 2): S134-S141.
19. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992; 326: 1456-1463.
20. Emir S, Kutluk T, Chan KW, Yalçin B, Varli K, Büyükpamukçu M. Peripheral neuropathy during α-interferon therapy in a child with Hodgkin's disease. Pediatr Hematol Oncol 1999; 16: 557-560.
21. Lazarus HM, Loberiza Jr FR, Zhang MJ, Armitage JO, Ballem KK, Bashey A et al. Autotransplants for Hodgkin's disease in first relapse or second remission: A report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant 2001; 27: 387-396.
22. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999; 341: 1165-1173.
23. Klingemann H-G, Grigg AP, Wilkie-Boyd K, Barnett MJ, Eaves AC, Reece DE et al. Treatment with recombinant interferon (α-2β) early after bone marrow transplantation in patients at high risk for relapse. Blood 1991; 78: 3306-3311.
24. Schenkein DP, Dixon P, Desforges JF, Berkman E, Erban JK, Ascensao JL et al. Phase I/II study of cyclophosphamide, carboplatin, and etoposide and autologous hematopoietic stem-cell transplantation with posttransplant interferon alfa-2b for patients with lymphoma and Hodgkins' disease. J Clin Oncol 1994; 12: 2423-2431.
25. Deschler B, Reincke M, Bley TA, Blink I, Engelhardt M. Striking complete remission after interferon-alpha for secondary recurrent non-Hodgkin's lymphoma but rare interferon-induced side effects. Ann Hematol 2005; 84: 263-266.
26. Ozawa S, Shinohara H, Kanayama HO, Bruns CJ, Bucana CD, Ellis LM et al. Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-α. Neoplasia 2001; 3: 154-164.
27. Schellong G, Dorffel W, Claviez A, Korholz D, Mann G, Scheel-Walter HG et al. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. J Clin Oncol 2005; 23: 6181-6189.
28. Ozkaynak MF, Jayabose S. Gemcitabine and vinorelbine as a salvage regimen for relapse in Hodgkin lymphoma after autologous hematopoietic stem cell transplantation. Pediatr Hematol Oncol 2004; 21: 107-113.